BriaCell Announces DSMB Recommends Continuation Of Phase 3 Bria-IMT Study For Metastatic Breast Cancer; No Safety Concerns Found; Study Under FDA Fast Track Designation

Author: Benzinga Newsdesk | March 20, 2025 07:06am

• The Data Safety Monitoring Board (DSMB) identified no safety concerns, and recommended continuation of BriaCell's pivotal Phase 3 study of Bria-IMT™ plus immune check point inhibitor in metastatic breast cancer
• The pivotal Phase 3 study is currently under Fast Track Designation with the Food and Drug Administration (FDA)

PHILADELPHIA and VANCOUVER, British Columbia, March 20, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the external Data Safety Monitoring Board (DSMB), an independent group of experts who review and monitor the safety data of the BriaCell clinical study to determine if the study should continue, be modified, or be halted, has completed its second safety data review of BriaCell's pivotal Phase 3 study of Bria-IMT plus immune checkpoint inhibitor (CPI) in metastatic breast cancer (NCT06072612) and recommended continuation of the ongoing study without any modifications. BriaCell's pivotal Phase 3 study is currently being conducted under Fast Track Designation with the Food and Drug Administration (FDA).

Posted In: BCTX TSX:BCT